Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Located in the Conejo Valley, Amgen is the world's largest independent biotechnology firm. In 2013, the company's largest selling product lines were Neulasta/Neupogen, two closely related drugs used to prevent infections in patients undergoing cancer chemotherapy; and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA.
The word AMGen is a portmanteau of the company's original name, Applied Molecular Genetics, which became the official name of the company in 1983 (three years after incorporation and coincident with its initial public offering). The company's first chief executive officer, from 1980, was co-founder George B. Rathmann, followed by Gordon M. Binder in 1988, followed by Kevin W. Sharer in 2000. Robert A. Bradway became Amgen’s president and chief executive officer in May 2012 following Sharer's retirement.
The company has made at least five major corporate acquisitions.
The following is an illustration of the company's mergers, acquisitions, spin-offs and historical predecessors:
(Founded 1983 as Applied Molecular Genetics)
Kinetix Pharmaceuticals Inc
Tularik Inc (Acq 2004)
Alantos Pharmaceuticals Holdings Inc
BioVex Group Inc
Laboratório Químico Farmacêutico Bergamo Ltda
Mustafa Nevzat İlaç
(Spun off 2013)
As of December, 2013, Amgen had twelve approved drugs or therapeutic biologicals for seventeen conditions (conditions lists are highly generalized; see each article for more detail):
As of December 2013, Amgen had 11 drugs in Phase III clinical trials.
In November 2014 the company announced it was halting all trials of rilotumumab in advanced gastric cancer patients after one of the trials found more deaths in those who took the compound with chemotherapy, than those without. Later in the same week, the company (in conjunction with AstraZeneca) reported positive results for brodalumab in a phase III trial comparing the compound with ustekinumab and a placebo in treating psoriasis.
In March 2015, the company announced it would license its Phase II candidate drug AMG 714 to developer Celimmune who plan to develop the anti-IL-15 monoclonal antibody for treatment against diet nonresponsive celiac disease and refractory celiac disease.
In June 2015 Amgen presented Phase 2 clinical trial data for their anti-CGRP antibody AMG 334 for migraine.